CASI Pharmaceuticals Newsroom

HC Wainwright & Co. : The CASI Pharmaceuticals (CASI.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $6.00.

Zhitong FinanceMay 15 23:51

CASI Pharmaceuticals Analyst Ratings

BenzingaMay 15 23:50

HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $6

BenzingaMay 15 23:50

CASI Pharmaceuticals Analyst Ratings

BenzingaNov 15, 2023 20:39

HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $10 Price Target

BenzingaAug 14, 2023 18:36

CASI Pharmaceuticals Analyst Ratings

BenzingaAug 14, 2023 18:35

Analysts Are Bullish on Top Healthcare Stocks: CASI Pharmaceuticals (CASI), Mirum Pharmaceuticals (MIRM)

TipRanksMay 22, 2023 18:30

HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $10 Price Target

BenzingaMay 22, 2023 18:17

Analysts Offer Insights on Healthcare Companies: Apyx Medical (APYX), CASI Pharmaceuticals (CASI) and CVRx (CVRX)

TipRanksApr 28, 2023 21:02

CASI Pharmaceuticals Analyst Ratings

Benzinga Analyst RatingsNov 16, 2022 21:46

CASI Pharmaceuticals Analyst Ratings

Benzinga Analyst RatingsNov 15, 2022 19:29